Australia-based biotech firm Propanc Biopharma (NASDAQ: PPCB) has announced a major step in its expansion into digital assets, securing up to $100 million in financing through a strategic agreement with Hexstone Capital, a prominent family office investor.
The company revealed on Monday that it has already received an initial $1 million investment, with an additional $99 million available over the next 12 months under the terms of a convertible preferred stock deal.
Strengthening Digital Asset and Biotech Operations
Propanc said the financing will support its dual-track strategy — expanding its digital asset treasury (DAT) portfolio while advancing its core biopharmaceutical research focused on metastatic cancer.
“We are entering a transformative phase for the company as we work on building our digital asset base and strengthening our balance sheet, which will enable us to accelerate our unique proenzyme technology to clinical development and beyond,” said James Nathanielsz, CEO of Propanc Biopharma.
The company plans to allocate a portion of the funds toward acquiring undervalued Digital Asset Treasury (DAT) companies, targeting firms whose market capitalization currently trades below their net asset value. This approach, according to Propanc, is designed to unlock additional shareholder value and diversify revenue streams.
Hexstone’s Track Record in Digital Assets
The financing partner, Hexstone Capital, is known for its investments in digital asset treasury firms that hold portfolios across Bitcoin, Ethereum, Solana, Dogecoin, and Injective, among others.
By partnering with Hexstone, Propanc aims to leverage that experience to diversify its balance sheet and build long-term exposure to the digital asset sector — an uncommon move for a biotech company but one the firm views as strategically forward-looking.
A Broader Vision for Growth
Propanc’s management has framed this initiative as part of a broader capital efficiency and innovation strategy that merges biotechnology and blockchain finance.
The company believes that integrating digital asset investment with its cancer research pipeline could enhance funding flexibility while accelerating the commercialization of its proenzyme therapy, a treatment approach designed to target and prevent cancer metastasis.
Positioning for the Future
The $100 million commitment marks one of the largest financing arrangements for a small-cap biotech firm with a stated focus on digital assets. Propanc says it views this hybrid model — combining traditional life sciences with next-generation financial assets — as a way to strengthen long-term growth and attract a new class of investors.
Earlier this month, Propanc outlined its initial Digital Asset Treasury strategy, positioning itself to acquire and manage digital assets as part of its treasury management plan.
With the Hexstone partnership now in place, the company is poised to accelerate both its crypto diversification and clinical research programs, advancing toward what management calls “a new phase of sustainable innovation and shareholder value creation.”
 has announced a major step in its expansion into digital asset...){kind=link}